[SCHEDULE 13G/A] Dianthus Therapeutics, Inc. SEC Filing
Venrock-related investors report a 1,000,000-share position in Dianthus Therapeutics (DNTH), representing 3.1% of the outstanding common stock. The disclosed holdings break down into 75,943 shares held by Venrock Healthcare Capital Partners III, 7,588 shares held by VHCP Co-Investment Holdings III, and 916,469 shares held by Venrock Healthcare Capital Partners EG. The reporting group states these shares were not acquired to influence or change control of the company. The percentage ownership is calculated using 32,159,982 shares outstanding as reported in the issuer's prior SEC filing.
Investitori legati a Venrock segnalano una posizione di 1.000.000 di azioni di Dianthus Therapeutics (DNTH), corrispondente al 3,1% del capitale sociale ordinario in circolazione. Le partecipazioni dichiarate si suddividono in 75.943 azioni detenute da Venrock Healthcare Capital Partners III, 7.588 azioni detenute da VHCP Co-Investment Holdings III e 916.469 azioni detenute da Venrock Healthcare Capital Partners EG. Il gruppo che effettua la segnalazione dichiara che queste azioni non sono state acquistate con l'intento di influenzare o modificare il controllo della societ脿. La percentuale di partecipazione 猫 calcolata sulla base di 32.159.982 azioni in circolazione, come riportato nel precedente deposito SEC dell'emittente.
Los inversores relacionados con Venrock informan de una posici贸n de 1.000.000 de acciones de Dianthus Therapeutics (DNTH), que representan el 3,1% del capital social ordinario en circulaci贸n. Las participaciones divulgadas se desglosan en 75.943 acciones en poder de Venrock Healthcare Capital Partners III, 7.588 acciones en VHCP Co-Investment Holdings III y 916.469 acciones en Venrock Healthcare Capital Partners EG. El grupo informante declara que estas acciones no fueron adquiridas con el fin de influir o cambiar el control de la compa帽铆a. El porcentaje de participaci贸n se calcula utilizando 32.159.982 acciones en circulaci贸n, seg煤n figura en la presentaci贸n previa ante la SEC del emisor.
氩る(Venrock) 甏�霠� 韴瀽鞛愲摛鞚� 霐旍晥靹滌姢 韰岆澕頁嫳鞀�(Dianthus Therapeutics, DNTH)鞚� 欤检嫕 1,000,000欤茧ゼ 氤挫湢 欷戩澊霛缄碃 氤搓碃頄堨溂氅�, 鞚措姅 鞙犿喌 欷戩澑 氤错喌欤� 齑濎垬鞚� 3.1%鞐� 頃措嫻頃╇媹雼�. 瓿店皽霅� 氤挫湢 雮挫棴鞚� Venrock Healthcare Capital Partners III臧� 氤挫湢頃� 75,943欤�, VHCP Co-Investment Holdings III臧� 氤挫湢頃� 7,588欤�, Venrock Healthcare Capital Partners EG臧� 氤挫湢頃� 916,469欤茧 甑劚霅╇媹雼�. 氤搓碃 攴鸽９鞚� 鞚� 欤检嫕霌れ澊 須岇偓鞚� 歆�氚瓣秾鞚� 頄夓偓頃橁卑雮� 氤�瓴巾晿旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頄堨姷雼堧嫟. 歆�攵� 牍勳湪鞚� 氚滍枆靷皜 鞚挫爠 SEC 氤搓碃靹滌棎 旮办灛頃� 32,159,982欤检潣 鞙犿喌 欤检嫕鞚� 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
Des investisseurs li茅s 脿 Venrock d茅clarent une position de 1 000 000 d'actions de Dianthus Therapeutics (DNTH), repr茅sentant 3,1 % du capital social ordinaire en circulation. Les avoirs divulgu茅s se r茅partissent en 75 943 actions d茅tenues par Venrock Healthcare Capital Partners III, 7 588 actions d茅tenues par VHCP Co-Investment Holdings III et 916 469 actions d茅tenues par Venrock Healthcare Capital Partners EG. Le groupe d茅clarante indique que ces actions n'ont pas 茅t茅 acquises dans le but d'influencer ou de changer le contr么le de la soci茅t茅. Le pourcentage de participation est calcul茅 en utilisant 32 159 982 actions en circulation, tel que rapport茅 dans le d茅p么t SEC ant茅rieur de l'茅metteur.
Venrock-nahe Investoren melden eine Position von 1.000.000 Aktien an Dianthus Therapeutics (DNTH), was 3,1 % des ausstehenden Stammkapitals entspricht. Die offengelegten Best盲nde gliedern sich in 75.943 Aktien, die von Venrock Healthcare Capital Partners III gehalten werden, 7.588 Aktien von VHCP Co-Investment Holdings III und 916.469 Aktien von Venrock Healthcare Capital Partners EG. Die meldende Gruppe erkl盲rt, dass diese Aktien nicht erworben wurden, um die Kontrolle 眉ber das Unternehmen zu beeinflussen oder zu 盲ndern. Die prozentuale Beteiligung wurde auf der Grundlage von 32.159.982 ausstehenden Aktien berechnet, wie sie in der vorherigen SEC-Einreichung des Emittenten angegeben sind.
- Transparent disclosure of aggregate 1,000,000-share position in Dianthus Therapeutics (DNTH).
- Clear breakdown of holdings: 75,943; 7,588; and 916,469 shares, improving investor clarity.
- Certification of passive intent stating shares were not acquired to change or influence control.
- None.
Insights
TL;DR: A coordinated 3.1% stake by Venrock entities is a disclosed passive holding below activist thresholds and unlikely to be market-moving.
The filing shows an aggregate 1,000,000-share position across multiple Venrock vehicles, with the largest component held by VHCP EG at 916,469 shares. At 3.1% of the 32,159,982-share base, this stake is below typical disclosure thresholds for control intent and below common 5% significance markers for material influence. The certification that shares were not acquired to change control indicates a passive intent under Schedule 13G rules. Investors should note the consolidated reporting by several related entities, which clarifies voting and dispositive powers.
TL;DR: Group filing consolidates related Venrock entities and affirms non-control intent, providing transparency on voting and disposition powers.
The Schedule 13G/A lists multiple Delaware-organized Venrock entities and two individual reporting persons, each reporting shared voting and dispositive power over the same 1,000,000 shares. The statement includes a certification that the stake is not held to influence control, consistent with passive investor classification under Rule 13d-1(c). The filing also references powers of attorney and a joint filing agreement by exhibit, indicating formalized coordination among the reporters for disclosure purposes.
Investitori legati a Venrock segnalano una posizione di 1.000.000 di azioni di Dianthus Therapeutics (DNTH), corrispondente al 3,1% del capitale sociale ordinario in circolazione. Le partecipazioni dichiarate si suddividono in 75.943 azioni detenute da Venrock Healthcare Capital Partners III, 7.588 azioni detenute da VHCP Co-Investment Holdings III e 916.469 azioni detenute da Venrock Healthcare Capital Partners EG. Il gruppo che effettua la segnalazione dichiara che queste azioni non sono state acquistate con l'intento di influenzare o modificare il controllo della societ脿. La percentuale di partecipazione 猫 calcolata sulla base di 32.159.982 azioni in circolazione, come riportato nel precedente deposito SEC dell'emittente.
Los inversores relacionados con Venrock informan de una posici贸n de 1.000.000 de acciones de Dianthus Therapeutics (DNTH), que representan el 3,1% del capital social ordinario en circulaci贸n. Las participaciones divulgadas se desglosan en 75.943 acciones en poder de Venrock Healthcare Capital Partners III, 7.588 acciones en VHCP Co-Investment Holdings III y 916.469 acciones en Venrock Healthcare Capital Partners EG. El grupo informante declara que estas acciones no fueron adquiridas con el fin de influir o cambiar el control de la compa帽铆a. El porcentaje de participaci贸n se calcula utilizando 32.159.982 acciones en circulaci贸n, seg煤n figura en la presentaci贸n previa ante la SEC del emisor.
氩る(Venrock) 甏�霠� 韴瀽鞛愲摛鞚� 霐旍晥靹滌姢 韰岆澕頁嫳鞀�(Dianthus Therapeutics, DNTH)鞚� 欤检嫕 1,000,000欤茧ゼ 氤挫湢 欷戩澊霛缄碃 氤搓碃頄堨溂氅�, 鞚措姅 鞙犿喌 欷戩澑 氤错喌欤� 齑濎垬鞚� 3.1%鞐� 頃措嫻頃╇媹雼�. 瓿店皽霅� 氤挫湢 雮挫棴鞚� Venrock Healthcare Capital Partners III臧� 氤挫湢頃� 75,943欤�, VHCP Co-Investment Holdings III臧� 氤挫湢頃� 7,588欤�, Venrock Healthcare Capital Partners EG臧� 氤挫湢頃� 916,469欤茧 甑劚霅╇媹雼�. 氤搓碃 攴鸽９鞚� 鞚� 欤检嫕霌れ澊 須岇偓鞚� 歆�氚瓣秾鞚� 頄夓偓頃橁卑雮� 氤�瓴巾晿旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頄堨姷雼堧嫟. 歆�攵� 牍勳湪鞚� 氚滍枆靷皜 鞚挫爠 SEC 氤搓碃靹滌棎 旮办灛頃� 32,159,982欤检潣 鞙犿喌 欤检嫕鞚� 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
Des investisseurs li茅s 脿 Venrock d茅clarent une position de 1 000 000 d'actions de Dianthus Therapeutics (DNTH), repr茅sentant 3,1 % du capital social ordinaire en circulation. Les avoirs divulgu茅s se r茅partissent en 75 943 actions d茅tenues par Venrock Healthcare Capital Partners III, 7 588 actions d茅tenues par VHCP Co-Investment Holdings III et 916 469 actions d茅tenues par Venrock Healthcare Capital Partners EG. Le groupe d茅clarante indique que ces actions n'ont pas 茅t茅 acquises dans le but d'influencer ou de changer le contr么le de la soci茅t茅. Le pourcentage de participation est calcul茅 en utilisant 32 159 982 actions en circulation, tel que rapport茅 dans le d茅p么t SEC ant茅rieur de l'茅metteur.
Venrock-nahe Investoren melden eine Position von 1.000.000 Aktien an Dianthus Therapeutics (DNTH), was 3,1 % des ausstehenden Stammkapitals entspricht. Die offengelegten Best盲nde gliedern sich in 75.943 Aktien, die von Venrock Healthcare Capital Partners III gehalten werden, 7.588 Aktien von VHCP Co-Investment Holdings III und 916.469 Aktien von Venrock Healthcare Capital Partners EG. Die meldende Gruppe erkl盲rt, dass diese Aktien nicht erworben wurden, um die Kontrolle 眉ber das Unternehmen zu beeinflussen oder zu 盲ndern. Die prozentuale Beteiligung wurde auf der Grundlage von 32.159.982 ausstehenden Aktien berechnet, wie sie in der vorherigen SEC-Einreichung des Emittenten angegeben sind.
FAQ
How many Dianthus Therapeutics (DNTH) shares did the Venrock group report?
What percentage of DNTH does the 1,000,000-share position represent?
How are the 1,000,000 shares allocated among the reporting entities?
Does the filing indicate an intent to influence control of Dianthus Therapeutics?
Which entities and individuals are part of the reporting group?
